The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 27, 2018

Filed:

Sep. 05, 2012
Applicants:

Christina Barnes Cooley, San Diego, CA (US);

Erika Geihe Stanzl, Stanford, CA (US);

Robert M. Waymouth, Stanford, CA (US);

Paul Wender, Menlo Park, CA (US);

Inventors:

Christina Barnes Cooley, San Diego, CA (US);

Erika Geihe Stanzl, Stanford, CA (US);

Robert M. Waymouth, Stanford, CA (US);

Paul Wender, Menlo Park, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A01N 37/12 (2006.01); A01N 37/44 (2006.01); A61K 9/127 (2006.01); A61K 9/00 (2006.01); A61K 47/59 (2017.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 9/0019 (2013.01); A61K 47/593 (2017.08); C12N 2310/14 (2013.01); C12N 2320/32 (2013.01);
Abstract

Co-oligomer compounds, complexes of the same with polyanions, such as siRNAs, and methods for using the same are provided. the delivery of polynucleotides, into a cell. The subject co-oligomers include at least a liphopilic monomer and at least a hydrophilic monomer (e.g., a guanidinium containing monomer). In some embodiments, the co-oligomer compounds are capable of complexing a siRNA of interest, thereby increasing the cell permeability of the siRNA, prior to release of the siRNA into the cell. In some embodiments, the subject method is a method of delivery a siRNA into a cell. In some embodiments, the subject method is a method of reducing expression of a protein target of a siRNA of interest. The subject co-oligomer/siRNA complexes may be formulated and administered to a subject to treat a condition resulting from expression of a protein target of the siRNA of interest.


Find Patent Forward Citations

Loading…